Home/Pipeline/TLR-011 (Nabiximols)

TLR-011 (Nabiximols)

Glioblastoma Multiforme

Phase 2Active

Key Facts

Indication
Glioblastoma Multiforme
Phase
Phase 2
Status
Active
Company

About Tilray

Tilray's mission is to be the world's leading cannabis-focused consumer branded goods and pharmaceutical company. Its key achievements include establishing one of the largest global footprints in cannabis cultivation and distribution, successfully merging with Aphria to create an industry leader, and building a clinical pipeline targeting serious conditions like glioblastoma and epilepsy. The company's strategy is to drive growth through its diversified portfolio—spanning cannabis, beverage alcohol, and wellness products—while investing in high-value pharmaceutical R&D to unlock long-term value from cannabinoid science.

View full company profile

Other Glioblastoma Multiforme Drugs

DrugCompanyPhase
Aldoxorubicin (LADR-7)LadRxPhase 2
INV441invIOsPre-clinical
certepetide (LSTA1)Lisata TherapeuticsPhase 1/2
WP1122Moleculin BiotechPreclinical/Phase 1